Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

WYOST

DENOSUMAB-BBDZ

Standard Dose
120MG/1.7ML (70MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview WYOST is listed in Drugs@FDA under application 761362 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DENOSUMAB-BBDZ Form and strength INJECTABLE;SUBCUTANEOUS - 120MG/1.7ML (70MG/ML) Sponsor SANDOZ INC Submission history Latest submission status date: 2025-10-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview WYOST is listed in Drugs@FDA under application 761362 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient DENOSUMAB-BBDZ Form and strength INJECTABLE;SUBCUTANEOUS - 120MG/1.7ML (70MG/ML) Sponsor SANDOZ INC Submission history Latest submission status date: 2025-10-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.